Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Volanesorsen (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 27 Jun 2016 According to an Akcea Therapeutics media release, data from this study were published in Diabetes Care.
- 27 Jun 2016 Results published in an Akcea Therapeutics media release.
- 06 Jun 2016 Primary endpoint has been met. (Total apoC-III), as per results published in the Diabetes Care.